Published in Cancer Weekly, November 6th, 2001
The new data strongly indicate that Campath can be effective as first-line therapy for T-PLL, which would represent another step forward in Schering's strategy to strengthen its role in different indications in the field of hematological oncology.
Campath was approved in the U.S. and Europe (trade name in Europe: MabCampath) earlier this year (2001) and is currently available to patients with B-cell chronic lymphocytic leukemia (B-CLL), who have been...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.